Potential therapeutic targeting of platelet-mediated cellular interactions in atherosclerosis and inflammation

B. Nagy, K. Miszti-Blasius, A. Kerényi, K. J. Clemetson, J. Kappelmayer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Cellular interactions among platelets, leukocytes and endothelial cells are considered as a major cause of inflammation and atherosclerosis in many diseases. Via exposed surface receptors and released soluble substances, activated platelets play a crucial role in the initiation of inflammatory processes, resulting in endothelial injury and leading to formation of atherosclerotic plaque with possible thrombotic complications. Classic anti-platelet treatments (e.g. cyclooxygenase inhibitor or ADP-receptor antagonist) have favorable effects in patients with vascular diseases, but they also have several limitations such as increased bleeding risk or non-responsiveness. Thus, the need and opportunities for developing novel therapeutic inhibitors for platelet-mediated events are obvious. Animal and (pre)clinical human studies have suggested that some recently produced specific antagonists of P-selectin from granules, as well as its main ligand/receptor P-selectin Glycoprotein Ligand-1, the two major platelet chemokines CXCL4 and CCL5, as well as CD40L, may be considered potential new candidates in the treatment of atherogenesis and inflammation. In this review, we summarize the pathophysiological roles of these effectors in platelet activation and acute or chronic inflammation, and discuss the latest findings on promising antagonistic agents in basic and clinical studies in the prevention of platelet-mediated cellular interactions.

Original languageEnglish
Pages (from-to)518-531
Number of pages14
JournalCurrent Medicinal Chemistry
Volume19
Issue number4
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Platelets
Atherosclerosis
Blood Platelets
Inflammation
Purinergic P2Y Receptor Antagonists
Platelet Factor 4
Therapeutics
Chemokine CCL5
CD40 Ligand
P-Selectin
Cyclooxygenase Inhibitors
Platelet Aggregation Inhibitors
Platelet Activation
Atherosclerotic Plaques
Vascular Diseases
Endothelial cells
Leukocytes
Endothelial Cells
Hemorrhage
Ligands

Keywords

  • Antiplatelet therapy
  • Atherosclerosis
  • CD40L
  • Chemokine
  • Endothelial cell
  • Inflammation
  • Leukocyte
  • Microparticle
  • P-selectin
  • Plaque formation
  • Platelet
  • PSGL-1
  • Vascular disorder

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Potential therapeutic targeting of platelet-mediated cellular interactions in atherosclerosis and inflammation. / Nagy, B.; Miszti-Blasius, K.; Kerényi, A.; Clemetson, K. J.; Kappelmayer, J.

In: Current Medicinal Chemistry, Vol. 19, No. 4, 02.2012, p. 518-531.

Research output: Contribution to journalArticle

@article{809b4d08673b409fb48e074cd83a60d4,
title = "Potential therapeutic targeting of platelet-mediated cellular interactions in atherosclerosis and inflammation",
abstract = "Cellular interactions among platelets, leukocytes and endothelial cells are considered as a major cause of inflammation and atherosclerosis in many diseases. Via exposed surface receptors and released soluble substances, activated platelets play a crucial role in the initiation of inflammatory processes, resulting in endothelial injury and leading to formation of atherosclerotic plaque with possible thrombotic complications. Classic anti-platelet treatments (e.g. cyclooxygenase inhibitor or ADP-receptor antagonist) have favorable effects in patients with vascular diseases, but they also have several limitations such as increased bleeding risk or non-responsiveness. Thus, the need and opportunities for developing novel therapeutic inhibitors for platelet-mediated events are obvious. Animal and (pre)clinical human studies have suggested that some recently produced specific antagonists of P-selectin from granules, as well as its main ligand/receptor P-selectin Glycoprotein Ligand-1, the two major platelet chemokines CXCL4 and CCL5, as well as CD40L, may be considered potential new candidates in the treatment of atherogenesis and inflammation. In this review, we summarize the pathophysiological roles of these effectors in platelet activation and acute or chronic inflammation, and discuss the latest findings on promising antagonistic agents in basic and clinical studies in the prevention of platelet-mediated cellular interactions.",
keywords = "Antiplatelet therapy, Atherosclerosis, CD40L, Chemokine, Endothelial cell, Inflammation, Leukocyte, Microparticle, P-selectin, Plaque formation, Platelet, PSGL-1, Vascular disorder",
author = "B. Nagy and K. Miszti-Blasius and A. Ker{\'e}nyi and Clemetson, {K. J.} and J. Kappelmayer",
year = "2012",
month = "2",
doi = "10.2174/092986712798918770",
language = "English",
volume = "19",
pages = "518--531",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Potential therapeutic targeting of platelet-mediated cellular interactions in atherosclerosis and inflammation

AU - Nagy, B.

AU - Miszti-Blasius, K.

AU - Kerényi, A.

AU - Clemetson, K. J.

AU - Kappelmayer, J.

PY - 2012/2

Y1 - 2012/2

N2 - Cellular interactions among platelets, leukocytes and endothelial cells are considered as a major cause of inflammation and atherosclerosis in many diseases. Via exposed surface receptors and released soluble substances, activated platelets play a crucial role in the initiation of inflammatory processes, resulting in endothelial injury and leading to formation of atherosclerotic plaque with possible thrombotic complications. Classic anti-platelet treatments (e.g. cyclooxygenase inhibitor or ADP-receptor antagonist) have favorable effects in patients with vascular diseases, but they also have several limitations such as increased bleeding risk or non-responsiveness. Thus, the need and opportunities for developing novel therapeutic inhibitors for platelet-mediated events are obvious. Animal and (pre)clinical human studies have suggested that some recently produced specific antagonists of P-selectin from granules, as well as its main ligand/receptor P-selectin Glycoprotein Ligand-1, the two major platelet chemokines CXCL4 and CCL5, as well as CD40L, may be considered potential new candidates in the treatment of atherogenesis and inflammation. In this review, we summarize the pathophysiological roles of these effectors in platelet activation and acute or chronic inflammation, and discuss the latest findings on promising antagonistic agents in basic and clinical studies in the prevention of platelet-mediated cellular interactions.

AB - Cellular interactions among platelets, leukocytes and endothelial cells are considered as a major cause of inflammation and atherosclerosis in many diseases. Via exposed surface receptors and released soluble substances, activated platelets play a crucial role in the initiation of inflammatory processes, resulting in endothelial injury and leading to formation of atherosclerotic plaque with possible thrombotic complications. Classic anti-platelet treatments (e.g. cyclooxygenase inhibitor or ADP-receptor antagonist) have favorable effects in patients with vascular diseases, but they also have several limitations such as increased bleeding risk or non-responsiveness. Thus, the need and opportunities for developing novel therapeutic inhibitors for platelet-mediated events are obvious. Animal and (pre)clinical human studies have suggested that some recently produced specific antagonists of P-selectin from granules, as well as its main ligand/receptor P-selectin Glycoprotein Ligand-1, the two major platelet chemokines CXCL4 and CCL5, as well as CD40L, may be considered potential new candidates in the treatment of atherogenesis and inflammation. In this review, we summarize the pathophysiological roles of these effectors in platelet activation and acute or chronic inflammation, and discuss the latest findings on promising antagonistic agents in basic and clinical studies in the prevention of platelet-mediated cellular interactions.

KW - Antiplatelet therapy

KW - Atherosclerosis

KW - CD40L

KW - Chemokine

KW - Endothelial cell

KW - Inflammation

KW - Leukocyte

KW - Microparticle

KW - P-selectin

KW - Plaque formation

KW - Platelet

KW - PSGL-1

KW - Vascular disorder

UR - http://www.scopus.com/inward/record.url?scp=84857584953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857584953&partnerID=8YFLogxK

U2 - 10.2174/092986712798918770

DO - 10.2174/092986712798918770

M3 - Article

C2 - 22204330

AN - SCOPUS:84857584953

VL - 19

SP - 518

EP - 531

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 4

ER -